The neurodevelopmental hypothesis of Schizophrenia, revisited

Schizophrenia Bulletin

Volumn 35, Issue 3, 2009, Pages 528-548

  Fatemi, S Hossein ^a,b   Folsom, Timothy D ^a  

^a Division of Neuroscience Research   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Animal model; Antiviral model; Brain; Epidemiology; Genes; Pathology; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; REELIN; VALPROIC ACID;

APOPTOSIS; BACTERIAL INFECTION; BIRTH RATE; CELL MIGRATION; CELL PROLIFERATION; DRUG ABUSE; ENVIRONMENTAL FACTOR; GABAERGIC SYSTEM; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE INTERACTION; GENETIC RISK; GLIA CELL; GRAY MATTER; HERITABILITY; HISTOPATHOLOGY; HUMAN; HYPOXIA; INCIDENCE; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NONHUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYNAPTOGENESIS; VIRUS INFECTION; WHITE MATTER;

ADOLESCENT; ADULT; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; INFANT, NEWBORN; MUTATION; NERVE NET; NEURODEGENERATIVE DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VIRUS DISEASES; YOUNG ADULT;

EID: 65349191920     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn187     Document Type: Review

References (223)

1. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 2005;10:434-449.
2. Fatemi SH. Prenatal viral infection, brain development and schizophrenia. In: Fatemi SH, ed. Neuropsychiatric Disorders and Infection. London, UK: Taylor and Francis; 2005.
3. Krapelin E. Psychiatrie. 4th ed. Ein lehrbuch für studirende und ärzte [Psychiatry 4th Ed: A Textbook for Students and Physicians]. Leipzeig, Germany: Abel; 1893.
4. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004;61:774-780.
5. Fatemi SH. Schizophrenia. In: Fatemi SH, Clayton PJ, eds. Medical Basis of Psychiatry. New York, NY: Humana Press; 2008:85-108.
6. Slater E, Beard AW, Glithero E. The schizophrenia-like psychoses of epilepsy. Br J Psychiatry. 1963;109:95-150.
7. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33:2061-2079.
8. Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res. 1999;33:513-521.
9. Keshavan MS, Hogarty GE. Brain maturational processes and delayed onset in schizophrenia. Dev Psychopathol. 1999;11:525-543.
10. Meltzer HY, Fatemi SH. Schizophrenia and other psychotic disorders. In: Ebert MH, Loosen PT, Nurcombe B, eds. Current Diagnosis and Treatment in Psychiatry. Norwalk, Conn: Appleton and Lange; 2000:260-277.
11. Lloyd T, Dazzan P, Dean K, et al. Minor physical anomalies in patients with first-episode psychosis: their frequency and diagnostic specificity. Psychol Med. 2008;38:71-77.
12. Bracha HS, Torrey EF, Gottesman II, Bigelow LB, Cunniff C. Second-trimester markers of fetal size in schizophrenia: a study of monozygotic twins. Am J Psychiatry. 1992;149: 1355-1361.
13. Avila MT, Sherr J, Valentine LE, Blaxton TA, Thaker GK. Neurodevelopmental interactions conferring risk for schizophrenia: a study of dermatoglyphic markers in patients and relatives. Schizophr Bull. 2003;29:595-605.
14. Fish B, Marcus J, Hans S, Auerbach JG, Perdue S. Infants at risk for schizohrenia: sequelae of a genetic neurointegrative defect. Arch Gen Psychiatry. 1992;49:221-235.
15. Walker EF. Developmentally moderated expressions of the neuropathology underlying schizophrenia. Schizophr Bull. 1994;20:453-480.
16. Barkus E, Stirling J, Hopkins R, Lewis S. The presence of neurological soft signs along the psychosis proneness continuum. Schizophr Bull. 2006;32:573-577.
17. Compton MT, Bollini AM, McKenzie ML, et al. Neurological soft signs and minor physical anomalies in patients with schizophrenia and related disorders, their first-degree biological relatives, and non-psychiatric controls. Schizophr Res. 2007;94:64-73.
18. Niemi LT, Suvisaari JM, Tuulio-Henriksson A, Lonnqvist JK. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res. 2003;60: 239-258.
19. Ott SL, Spinelli S, Rock D, Roberts S, Amminger GP, Erlenmeyer-Kimling L. The New York High-Risk Project: social and general intelligence in children at risk for schizophrenia. Schizophr Res. 1998;31:1-11.
20. Keshavan MS, Gilbert AR, Diwadkar VA. Neurodevelopmental theories. In: Lieberman JA, Stroup TS, Perkins DO, eds. The American Psychiatric Publishing Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing Inc.; 2006:69-84.
21. Gilmore JH, Murray RM. Prenatal and perinatal factors. In: Lieberman JA, Stroup TS, Perkins DO, eds. The American Psychiatric Publishing Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing Inc.; 2006:55-68.
22. Lewis DA. Retroviruses and the pathogenesis of schizophrenia. Proc Natl Acad Sci USA. 2001;94:4293-4294.
23. Karlsson H, Bachmann S, Schroder J, McArthur J, Torrey EF, Yolken RH. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci USA. 2001;98:4634-4639.
24. Hare EH, Price JS, Slater E. Schizophrenia and season of birth. Br J Psychiatry. 1972;120:125-126.
25. Machon RA, Mednick SA, Schulsinger F. The interaction of seasonality, place of birth, genetic risk and subsequent schizophrenia in a high risk sample. Br J Psychiatry. 1983; 143:383-388.
26. Susser ES, Brown AS, Gorman JM. Prenatal Exposures in Schizophrenia. Washington, DC: American Psychiatric Press; 1999.
27. Boyd JH, Pulver AE, Stewart W. Season of birth: schizophrenia and bipolar disorder. Schizophr Bull. 1986;12:173-186.
28. Pallast EG, Jongbloet PH, Straatman HM. Excess seasonality of births among patients with schizophrenia and seasonal ovopathy. Schizophr Bull. 1994;20:269-276.
29. Pulver AE, Liang KY, Wolyniec PS. Season of birth among siblings of schizophrenic patients. Br J Psychiatry. 1992;160: 71-75.
30. Mednick SA, Machon RA, Huttunen MO. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry. 1988;45:189-192.
31. Stober G, Franzek E, Beckmann J. The role of maternal infectious diseases during pregnancy in the aetiology of schizophrenia in offspring. Eur Psychiatry. 1992;7:147-152.
32. Wright P, Rakei N, Rifkin L, Murray RM. Maternal influenza, obstetric complications, and schizophrenia. Am J Psychol. 1995;152:1714-1720.
33. Mednick SA, Huttunen MO, Macon RA. Prenatal influenza infections and adult schizophrenia. Schizophr Bull. 1994;20:263-267.
34. Brown AS, Cohen P, Greenwald S, Susser E. Nonaffective psychosis after prenatal exposure to rubella. Am J Psychiatry. 2000;157:438-443.
35. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull. 2006;32:200-202.
36. Nakai Y, Itoh M, Mizuguchi M, et al. Apoptosis and micro-glial activation in influenza encephalopathy. Acta Neuropathol. 2003;105:233-239.
37. Aronsson F, Robertson B, Ljunggren HG, Kristensson K. Invasion and persistence of the neuroadapted influenza virus A/WSN/33 in the mouse olfactory system. Viral Immunol. 2003;16:415-423.
38. Aronsson F, Lannebo C, Paucar M, Brask J, Kristensson K, Karlsson H. Persistence of viral RNA in the brain of offspring to mice infected with influenza A/WSN/33 during pregnancy. J Neurovirol. 2002;8:353-357.
39. Chen BY, Chang HH, Chiou HL, Lin DP. Influenza B virus-induced brain malformations during early chick embryogenesis and localization of tRNA in specific areas. J Biomed Sci. 2004;11:266-274.
40. Aronsson F, Karlsson H, Ljunggren HG, Kristensson K. Persistence of the influenza A/WSN/33 virus RNA at midbrain levels of immunodefective mice. J Neurovirol. 2001;7:117-124.
41. Levine J, Buchman CA, Fregien N. Influenza A virus infection of human Schwann cells in vitro. Acta Otolaryngol. 2003;123:41-45.
42. Brask J, Owe-Larsson B, Hill RH, Kristensson K. Changes in calcium currents and GABAergic spontaneous activity in cultured rat hippocampal neurons after a neurotropic influenza A virus infection. Brain Res Bull. 2001;55: 421-429.
43. Pearce BD, Valadi NM, Po CL, Miller AH. Viral infection of developing GABAergic neurons in a model of hippocampal disinhibition. Neuroreport. 2000;11:2433-2438.
44. Hillier SL, Witkin SS, Krohn MA, Watts DH, Kiviat NB, Eschenbach DA. The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection. Am J Obstet Gynecol. 1993;81:941-948.
45. Fortunado SJ, Menon RP, Swan KF, Menon R. Inflammatory cytokines (interleukins 1.6.8 and tumor necrosis factor-α) release from cultured fetal membranes in response to endotoxic lipopolysaccharide mirrors amniotic fluid. Am J Obstet Gynecol. 1996;174:1855-1862.
46. Fidel PL, Jr, Romero R, Wolf N, et al. Systemic and local cytokine profiles in endotoxin-induced preterm parturition in mice. Am J Obstet Gynecol. 1994;170:1467-1475.
47. Urkabo A, Jarskog LF, Lieberman JA, Gilmore JH. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res. 2001;47:27-36.
48. Yoon BH, Romero R, Moon J, et al. Differences in the fetal interleukin-6 response to microbial invasion of the amniotic cavity between term and preterm gestation. J Matern Fetal Neonatal Med. 2003;13:32-38.
49. BukaSL,TsuangMT,TorreyEF,KlebanoffMA,WagnerRL, Yolken RH. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun. 2001;15: 411-420.
50. Merrill JE. Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci. 1992;14:1-10.
51. Mehler MF, Kessler JA. Growth factor regulation of neuronal development. Dev Neurosci. 1994;16:180-195.
52. Mehler MF, Kessler JA. Hematolymphopoietic and inflammatory cytokines in neural development. Trends Neurosci. 1997;20:357-365.
53. Burns TM, Clough JA, Klein RM, Wood GW, Berman NE. Developmental regulation of cytokine expression in the mouse brain. Growth Factors. 1993;9:253-258.
54. Gadient RA, Otten U. Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. Brain Res. 1994;637:10-14.
55. Pousset F. Developmental expression of cytokine genes in the cortex and hippocampus of the rat central nervous system. Dev Brain Res. 1994;81:143-146.
56. Mousa A, Seiger A, Kjaeldgaard A, Bakhiet M. Human first trimester forebrain cells express genes for inflammatory and anti-inflammatory cytokines. Cytokine. 1999;11:55-60.
57. Dziegielewska KM, Moller JE, Potter AM, Ek J, Lane MA, Saunders NR. Acute-phase cytokines IL-1β and TNFα in brain development. Cell Tissue Res. 2000;299:235-245.
58. McDuffie RS, Dabies JK, Leslie KK, Sherman MP, Gibbs RS. A randomized control trail of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancy. Infect Dis Obstet Gynecol. 2001;9:233-237.
59. Menon R, Swan KF, Lyden TW, Rote NS, Fortunado SJ. Expression of inflammatory cytokines (interleukin-1β and interleukin-6) in amniochorionic membranes. Am J Obstet Gynecol. 1995;172:493-500.
60. Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci. 2003;23:297-302.
61. Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensori-motor gating in adult rats: implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology. 2002;26: 204-215.
62. Zuckerman L, Weiner I. Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology. 2003;169:308-313.
63. Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry. 1996;53:25-31.
64. Brown AS, Susser E. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr Bull. 2008;34:1054-1063.
65. Hollister JM, Laing P, Mednick SA. Rhesus incompatibility as a risk factor for schizophrenia in male adults. Arch Gen Psychiatry. 1996;53:19-24.
66. Wright P, Murray RM. Schizophrenia: prenatal influenza and autoimmunity. Ann Med. 1993;25:497-502.
67. Fatemi SH, Emamian ES, Kist D, et al. Defective cortico-genesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol Psychiatry. 1999;4:145-154.
68. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun. 2008;22:469-486.
69. Geyer MA, Braff DL, Swerdlow NR. Startle-response measures of information processing in animals: relevance to schizophrenia. In: Haug M, Whalen RE, eds. Animal Models of Human Emotion and Cognition. Washington, DC: American Psychiatric Press; 1999:103-116.
70. Fatemi SH, Earle JA, Kanodia R, et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cell Mol Neurobiol. 2002;22:25-33.
71. Fatemi SH, Reutiman TJ, Folsom TD, et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelop-mental disorders. Schizophr Res. 2008;99:56-70.
72. Fatemi SH, Pearce DA, Brooks AI, Sidwell R. Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse. 2005;57:91-99.
73. Fatemi SH, Reutiman TJ, Folsom TD, Sidwell R. The role of cerebellar genes in pathology of autism and schizophrenia. Cerebellum. 2008; In press.
74. Veldic M, Caruncho HJ, Liu WS. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci USA. 2004;101:348-353.
75. Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka W, Veldic M. Reviewing the role of DNA (cytosine-5) methyl-transferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics. 2007;2:29-36.
76. Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291-1293.
77. Verkman AS, Binder DK, Bloch O, Auguste K, Papadopoulos MC. Three distinct roles of aquaporin-4 in brain function revealed by knockout mice. Biochim Biophys Acta. 2006;1758:1085-1093.
78. Fatemi SH, Folsom TD, Reutiman TJ, Sidwell RW. Viral regulation of aquaporin 4, connexin 43, microcephalin and nucleolin. Schizophr Res. 2008;98:163-177.
79. Fatemi SH, Cuadra AE, El-Fakahany EE, Thuras P. Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. Neuroreport. 2000;11: 1493-1496.
80. Sullivan PF, Owen MJ, O'Donovan MC, Freedman MD. Genetics. In: Lieberman JA, Stroup TS, Perkins DO, eds. The American Psychiatric Publishing Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing Inc; 2006:39-54.
81. Owen MJ, Craddock N, O'Donovan MC. Schizophrenia: genes at last? Trends Genet. 2005;21:518-525.
82. Murphy KC. Schizophrenia and velo-cardio-facial syndrome. Lancet. 2002;359:426-430.
83. Paylor R, McIlwain KL, McAninch R, et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum Mol Genet. 2001;10:2645-2650.
84. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003;73:34-48.
85. Sullivan PF, Eaves LJ, Kendler KS, Neale MC. Genetic case-control association studies in neuropsychiatry. Arch Gen Psychiatry. 2001;58:1015-1024.
86. Levitt P, Ebert P, Mirnics K, Nimgaonkar VL, Lewis DA. Making the case for a candidate vulnerability gene in schizophrenia: convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol Psychiatry. 2006;60:534-537.
87. Le-Niculescu H, Balaraman Y, Patel S, et al. Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet. 2007;144:129-158.
88. Fatemi SH, Reutiman TJ, Folsom TD, et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology. 2006;31:1888-1899.
89. Hakak Y, Walker JR, Li C, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA. 2001;98:4746-4751.
90. Mirnics K, Lewis DA. Genes and subtypes of schizophrenia. Trends Mol Med. 2001;7:169-174.
91. Chung C, Tallerico T, Seeman P. Schizophrenia hippocampus has elevated expression of chondrex glycoprotein gene. Synapse. 2003;50:29-34.
92. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53-67.
93. Vawter MP, Crook JM, Hyde TM, et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res. 2002;58:11-20.
94. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003;23:6315-6326.
95. Marcotte ER, Srivastava LK, Quirion R. cDNA microarray and proteomic approaches in the study of brain diseases: focus on schizophrenia and Alzheimer's disease. Pharmacol Ther. 2003;100:63-74.
96. Pongrac J, Middleton FA, Lewis DA, Levitt P, Mirnics K. Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders. Neurochem Res. 2002;27:1049-1063.
97. Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 1995;52:258-278.
98. Fatemi SH, Stary JM, Earle JA. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res. 2005;72: 109-122.
99. Tkachev D, Mimmack ML, Ryan MM, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798-805.
100. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 2001;25:1-27.
101. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27-38.
102. Bowden NA, Scott RJ, Tooney PA. Altered gene expression in the superior temporal gyrus in schizophrenia. Biol Psychiatry. 2003;53:1086-1098.
103. Colantuoni C, Hyde TM, Mitkus S, et al. Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Struct Funct. 2008;213:255-271.
104. Preti A, Cardascia L, Zen T, et al. Risk for obstetric complications and schizophrenia. Psychiatry Res. 2000;96: 127-139.
105. Cannon TD, van Erp TG, Rosso IM, Marchetti M, Favaretto G, Miotto P. Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry. 2002;59:35-41.
106. Boog G. Obstetrical complications and subsequent schizophrenia in adolescent and young adult offsprings: is there a relationship? Eur J Obstet Gynecol Reprod Biol. 2004;114: 130-136.
107. Schmidt-Kastner R, van Os J, Steinbusch HMW, Schmitz C. Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophr Res. 2006;84:253-271.
108. Nicodemus KK, Marenco S, Batten AJ, et al. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry. 2008;13:873-877.
109. Lee JA, Lupski JR. Genomic rearrangements and gene copy-number alterations as a cause of nervous system disorders. Neuron. 2006;52:103-121.
110. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320:539-543.
111. The International Schizophrenia Consortium.Stone JL, O'Donovan MC, Gurling H, et al. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455:237-241.
112. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunc-tion in schizophrenia. Nat Med. 2006;12:824-828.
113. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry. 2001;158:1393-1399.
114. Addington AM, Gornick MC, Shaw P, et al. Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories. Mol Psychiatry. 2006;12:195-205.
115. Garcia RA, Vasudevan K, Buonanno A. The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses. Proc Natl Acad Sci USA. 2000;97: 3596-3601.
116. Buxbaum JD, Georgieva L, Young JJ, et al. Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Mol Psychiatry. 2008;13:162-172.
117. Kirschner MA, Arriza JL, Copeland NG, et al. The mouse and human excitatory amino acid transporter gene (EAAT1) maps to mouse chromosome 15 and a region of syntenic homology on human chromosome 5. Genomics. 1994;22:631-633.
118. Kitagawa M, Lee SH, McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell. 2008; 29:217-231.
119. Liu YL, Fann CS, Liu CM, et al. HTF9C gene of 22q11.21 region associates with schizophrenia having deficit-sustained attention. Psychiatr Genet. 2007;17:333-338.
120. Liu G, Beggs H, Jurgensen C, et al. Netrin requires focal adhesion kinase and Src family kinases for axon outgrowth and attraction. Nat Neurosci. 2004;7:1222-1232.
121. Kondo T, Raff MC. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev. 2004;18:2963-2972.
122. Carter CJ. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr Bull. 2008; In press.
123. Northoff G, Waters H, Mooren I, et al. Cortical sulcal enlargement in catatonic schizophrenia: a planimetric CT study. Psychiatry Res. 1999;91:45-54.
124. Meltzer HY, Bobo WV, Heckers SH, Fatemi SH. Schizophrenia. In: Ebert MH, Loosen PT, Nurcombe B, eds. Lange Current Series. New York, NY: McGraw Hill; 2008: pp. 261-288.
125. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157: 16-25.
126. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60:443-456.
127. Arnold SE, Trojanowski JQ. Recent advanced in defining the neuropathology of schizophrenia. Acta Neuropathol. 1997;92:217-231.
128. Andreasen NC. A unitary model of schizophrenia. Bleuler's "Fragmented phrene" as schizencephaly. Arch Gen Psychiatry. 1999;56:781-793.
129. Arnold SE. Cellular and molecular neuropathology of the parahippocampal region in schizophrenia. Ann N Y Acad Sci. 2000;911:275-292.
130. Bunney WE, Bunney BG. Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev. 2000;31:138-146.
131. Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry. 2003;53:1086-1098.
132. Akbarian S, Bunney WE, Jr, Potkin SG, et al. Altered distribution of nicotinamide - adenine - dinucleotide - phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry. 1993;50:169-177.
133. Ritter LM, Meador-Woodruff JH, Dalack GW. Neurocognitive measures of prefrontal cortical dysfunction in schizophrenia. Schizophr Res. 2004;68:65-73.
134. Schiller D, Zuckerman L, Weiner I. Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol. J Psychiatr Res. 2006;40:167-177.
135. Surguladze SA, Chu EM, Evans A, et al. The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study. J Clin Psychopharmacol. 2007;27:560-570.
136. Wolf RC, Höse A, Frasch K, Walter H, Vasic N. Volumetric abnormalities associated with cognitive deficits in patients with schizophrenia. Eur Psychiatry. 2008;23:541-548.
137. Weiss AP, Dewitt I, Goff D, Ditman T, Heckers S. Anterior and posterior hippocampal volumes in schizophrenia. Schizophr Res. 2005;73:103-112.
138. Connor SE, Ng V, McDonald C, et al. A study of hippocampal shape anomaly in schizophrenia and in families multiply affected by schizophrenia or bipolar disorder. Neuroradiology. 2004;46:523-534.
139. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry. 1999;48: 625-632.
140. Luts A, Jonsson SA, Guldberg-Kjaer N, Brun A. Uniform abnormalities in the hippocampus of five chronic schizophrenic men compared with age-matched controls. Acta Psychiatr Scand. 1998;98:60-64.
141. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003;361:417-419.
142. Uematsu M, Kaiya H. Midsagittal cortical pathomorphology of schizophrenia: a magnetic resonance imaging study. Psychiatry Res. 1989;30:11-20.
143. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 1997;74: 129-140.
144. Nopoulos PC, Ceilley JW, Gailis EA, Andreasen NC. An MRI study of cerebellar vermis morphology in patients with schizophrenia: evidence in support of the cognitive dysmetria concept. Biol Psychiatry. 1999;46: 703-711.
145. Goldman AL, Pezawas L, Mattay VS, et al. Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. Biol Psychiatry. 2008;63:475-483.
146. Meyer-Lindenberg A, Poline JB, Kohn PD, et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry. 2001;158: 1809-1817.
147. Riehemann S, Volz HP, Stutzer P, Smesny S, Gaser C, Sauer H. Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test-a fMRI study. Eur Arch Psychiatry Clin Neurosci. 2001;251: 66-71.
148. Kumari V, Gray JA, Goney GD, et al. Procedural learning in schizophrenia: a functional magnetic resonance imaging investigation. Schizophr Res. 2002;57:97-107.
149. Lim KO, Helpern JA. Neuropsychiatric applications of DTI - a review. NMR Biomed. 2002;15:587-593.
150. Ardekani BA, Nierenberg J, Hoptman MJ, Javitt DC, Lim KO. MRI study of white matter diffusion anisotropy in schizophrenia. Neuroreport. 2003;14:2025-2029.
151. Kubicki M, Westin CF, Nestor PG, et al. Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biol Psychiatry. 2003;54:1171-1180.
152. Bullmore ET, Frangou S, Murray RM. The dysplastic net hypothesis: an integration of developmental and dysconnectivity theories of schizophrenia. Schizophr Res. 1997;28: 143-156.
153. Buchsbaum MS, Tang CY, Peled S, et al. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. Neuroreport. 1998;9:425-430.
154. Lim KO,HedehusM,MoseleyM,deCrespignyA,SullivanEV, Pfefferbaum A. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch Gen Psychiatry. 1999;56:367-374.
155. Foong J, Maier M, Clark CA, Barker GJ, Miller DH, Ron MA. Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry. 2000;68:242-244.
156. Agartz I, Andersson JL, Skare S. Abnormal brain white matter in schizophrenia: a diffusion tensor imaging study. Neuroreport. 2001;12:2251-2254.
157. Burns J, Job D, Bastin ME, et al. Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br J Psychiatry. 2003;182:439-443.
158. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry. 2007;62:1396-1404.
159. Friedman JI, Davis KL, Chang L, Ernst T, Tsopelas ND, Zhong K. Relationships between white matter metabolite abnormalities, cognitive and social functioning in elderly schizophrenic subjects. Schizophr Res. 2008;100:356-358.
160. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: American Psychiatric Press; 1994.
161. Easton WW, Chen C-Y. Epidemiology. In: Lieberman JA, Stroup TS, Perkins DO, eds. The American Psychiatric Publishing Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing Inc; 2006:17-38.
162. Sartorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med. 1986;16: 909-928.
163. Hales RE, Yudofsky SC, Talbott JA. The American Psychiatric Press Textbook of Psychiatry. Washington, DC: American Psychiatric Press; 1999.
164. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60:565-571.
165. Harris MJ, Jeste DV. Late-onset schizophrenia: an overview. Schizophr Bull. 1988;14:39-55.
166. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 2000;157:172-178.
167. Palmer BW, McClure FS, Jeste DV. Schizophrenia in late life: findings challenge traditional concepts. Harv Rev Psychiatry. 2001;9:51-58.
168. Carter CS. Re-conceptualizing schizophrenia as a disorder of cognitive and emotional processing: a shot in the arm for translational research. Biol Psychiatry. 2006;60:1169-1170.
169. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187-1192.
170. Asherson P, Mane R, McGiffin P. Genetics and schizophrenia. In: Mirsch SR, Weinberger DR, eds. Schizophrenia. Boston, Mass: Blackwell Scientific; 1995:253-274.
171. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184:110-117.
172. Javitt DC, Laruelle M. Neurochemical theories. In: Lieberman JA, Stroup TS, Perkins DO, eds. The American Psychiatric Publishing Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing Inc; 2006:85-116.
173. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57:65-73.
174. Pierri JN, Volk CL, Auh S, Sampson A, Lewis DA. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry. 2001;58:466-473.
175. Beffert U, Weeber EJ, Durudas A, et al. Modulation of synaptic plasticity and memory by reelin involves differential splicing of the lipoprotein receptor apoer2. Neuron. 2005;47:567-579.
176. Fatemi SH. Reelin glycoprotein: structure, biology and roles in health and disease. Mol Psychiatry. 2005;10:251-257.
177. Impagnatiello F, Guidotti AR, Pesold C, et al. A decrease of Reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA. 1998;95:15718-15723.
178. Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000;57:1061-1069.
179. Fatemi SH, Earle JA, McMenomy T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry. 2000;5:571-654-663.
180. Fatemi SH, Reutiman TJ, Folsom TF. The role of reelin in etiology and treatment of psychiatric disorders. In: Fatemi SH, ed. Reelin Glycoprotein, Structure and Roles in Health and Disease. New York, NY: Springer; 2008:317-340.
181. Eastwood SL, Law AJ, Everall IP, Harrison PJ. The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathology. Mol Psychiatry. 2003;8:148-155.
182. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090.
183. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3 methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh). 1963;20:140-144.
184. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10:317-336.
185. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord. 2002;1:141-147.
186. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28:325-334.
187. Sim K, Cullen T, Ongur D, Heckers S. Testing models of thalamic dysfunction in schizophrenia using neuroimaging. J Neural Transm. 2006;113:907-928.
188. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
189. Sharif Z, Bradford D, Stroup S, Lieberman J. Pharmacological treatment of schizophrenia. In: Nathan PE, Gorman J, eds. A Guide to Treatments That Work. 3rd ed. New York, NY: Oxford University Press; 2007:203-242.
190. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228-1235.
191. Emsley R, Rabinowitz J, Medori R. Time course for anti-psychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006;163:743-745.
192. Chen ML, Chen CH. Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology. 2005;30:268-277.
193. Fatemi SH, Meltzer HY. (2000). Binding of olanzapine to serotonin receptors. In: Tran PV, Bymaster FP, Tye N, Herrera JM, Breier A, Tollefson GD, eds. Olanzapine (Zyprexa): A Novel Antipsychotic.Philadelphia, Pa: Lippincott, Williams and Wilkins; 2000:25-30.
194. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62:361-370.
195. Wang HD, Deutch AY. Olanzapine reverses dopamine depletion-induced dendritic spine loss in prefrontal cortical pyramidal neurons. 34th Annual Meeting of Society for Neuroscience. October, 2004, San Diego, CA
196. Frasca A, Fumagalli F, Ter Horst J, Racagni G, Murphy KJ, Riva MA. Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex. Int J Neuropsychopharmacol. 2008;11:591-595.
197. Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51:593-628.
198. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem. 1994;63:972-979.
199. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-o- methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci. 2004;24:5331-5335.
200. Fatemi SH, Folsom TD.Catechol-O-methyltransferase gene regulation in rat frontal cortex. Mol Psychiatry. 2007;12:322-323.
201. BoydellJ,vanOsJ,McKenzieK,MurrayRM. Theassociation of inequality with the incidence of schizophrenia-an ecological study. Soc Psychiatry Psychiatr Epidemiol. 2004;39:597-599.
202. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344:1398-1402.
203. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 2002;159:1080-1092.
204. Cantor-Graae E, Selten JP. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry. 2005;162:12-24.
205. Foong J, Symms MR, Barker GJ, Maier M, Miller DH, Ron MA. Investigating regional white matter in schizophrenia using diffusion tensor imaging. Neuroreport. 2002;13:333-336.
206. Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry. 2002;59:553-558.
207. Bertolino A, Kumra S, Callicott JH, et al. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 1998;155:1376-1383.
208. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999;46:729-739.
209. Rapoport JL, Giedd JN, Blumenthal J, et al. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry. 1999;56:649-654.
210. Nair TR, Christensen TD, Kingsbury SJ, Kumar NG, Terry WM, Garver DL. Progression of cerebroventricular enlargement and the subtyping of schizophrenia. Psychiatry Res. 1997;74:141-150.
211. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry. 2001;58:148-157.
212. Jarskog LF, Glantz LA, Gilmore JH. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:846-858.
213. Mattson MP, Duan W. "Apoptotic" biochemical cascades in synaptic compartments: roles in adaptive plasticity and neurodegenerative disorders. J Neurosci Res. 1999;58:152-166.
214. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry. 2000;48:641-650.
215. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry. 2004;161:109-115.
216. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407:802-809.
217. Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull. 1998;2: 425-435.
218. Wedenoja J, Loukola A, Tuulio-Henriksson A, et al. Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. Mol Psychiatry. 2008;13:673-684.
219. Perron H, Mekaoui L, Bernard C, Veas F, Stefas I, Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum schizophrenic patients. Biol Psychiatry. 2008;64:1019-1023.
220. Akbarian S. Restoring GABAergic signaling and neuronal synchrony in schizophrenia. Am J Psychiatry. 2008;165: 1507-1509.
221. Bullock WM, Cardon K, Bustillo J, Roberts RC, Perrone-Bizzozero NI. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry. 2008;165:1594-1603.
222. Sweet RA, Henteleff RA, Zhang W, Sampson AR, Lewis DA. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology. 2009;34: 374-389.
223. Fatemi SH, ed. Reelin Glycoprotein: Structure, Biology, and Roles in Health and Disease. New York: Springer.